Calpain inhibition is sufficient to suppress aggregation of polyglutamine-expanded ataxin-3
- PMID: 17488727
- DOI: 10.1074/jbc.M611914200
Calpain inhibition is sufficient to suppress aggregation of polyglutamine-expanded ataxin-3
Abstract
The formation of intraneuronal inclusions is a common feature of neurodegenerative polyglutamine disorders, including Spinocerebellar ataxia type 3. The mechanism that triggers inclusion formation in these typically late onset diseases has remained elusive. However, there is increasing evidence that proteolytic fragments containing the expanded polyglutamine segment are critically required to initiate the aggregation process. We analyzed ataxin-3 proteolysis in neuroblastoma cells and in vitro and show that calcium-dependent calpain proteases generate aggregation-competent ataxin-3 fragments. Co-expression of the highly specific cellular calpain inhibitor calpastatin abrogated fragmentation and the formation of inclusions in cells expressing pathological ataxin-3. These findings suggest a critical role of calpains in the pathogenesis of Spinocerebellar ataxia type 3.
Similar articles
-
Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3).Hum Mol Genet. 2013 Feb 1;22(3):508-18. doi: 10.1093/hmg/dds449. Epub 2012 Oct 24. Hum Mol Genet. 2013. PMID: 23100324
-
Proteolytic cleavage of polyglutamine-expanded ataxin-3 is critical for aggregation and sequestration of non-expanded ataxin-3.Hum Mol Genet. 2006 Feb 15;15(4):555-68. doi: 10.1093/hmg/ddi472. Epub 2006 Jan 11. Hum Mol Genet. 2006. PMID: 16407371
-
Calpastatin-mediated inhibition of calpains in the mouse brain prevents mutant ataxin 3 proteolysis, nuclear localization and aggregation, relieving Machado-Joseph disease.Brain. 2012 Aug;135(Pt 8):2428-39. doi: 10.1093/brain/aws177. Brain. 2012. PMID: 22843411
-
Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease.Prog Neurobiol. 2011 Sep 15;95(1):26-48. doi: 10.1016/j.pneurobio.2011.06.007. Epub 2011 Jun 28. Prog Neurobiol. 2011. PMID: 21740957 Review.
-
Mouse models of Machado-Joseph disease and other polyglutamine spinocerebellar ataxias.NeuroRx. 2005 Jul;2(3):480-3. doi: 10.1602/neurorx.2.3.480. NeuroRx. 2005. PMID: 16389311 Free PMC article. Review.
Cited by
-
Human Induced Pluripotent Stem Cell-Based Modelling of Spinocerebellar Ataxias.Stem Cell Rev Rep. 2022 Feb;18(2):441-456. doi: 10.1007/s12015-021-10184-0. Epub 2021 May 25. Stem Cell Rev Rep. 2022. PMID: 34031815 Free PMC article. Review.
-
Unbiased screen identifies aripiprazole as a modulator of abundance of the polyglutamine disease protein, ataxin-3.Brain. 2016 Nov 1;139(11):2891-2908. doi: 10.1093/brain/aww228. Brain. 2016. PMID: 27645800 Free PMC article.
-
Neuron-specific proteotoxicity of mutant ataxin-3 in C. elegans: rescue by the DAF-16 and HSF-1 pathways.Hum Mol Genet. 2011 Aug 1;20(15):2996-3009. doi: 10.1093/hmg/ddr203. Epub 2011 May 5. Hum Mol Genet. 2011. PMID: 21546381 Free PMC article.
-
Flow cytometry allows rapid detection of protein aggregates in cellular and zebrafish models of spinocerebellar ataxia 3.Dis Model Mech. 2021 Oct 1;14(10):dmm049023. doi: 10.1242/dmm.049023. Epub 2021 Oct 11. Dis Model Mech. 2021. PMID: 34473252 Free PMC article.
-
A mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado-Joseph disease-like transgenic mice.Neurobiol Dis. 2007 Sep;27(3):362-9. doi: 10.1016/j.nbd.2007.06.005. Epub 2007 Jun 13. Neurobiol Dis. 2007. PMID: 17632007 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources